spironolactone has been researched along with Endomyocardial Fibrosis in 20 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Endomyocardial Fibrosis: A condition characterized by the thickening of the ventricular ENDOCARDIUM and subendocardium (MYOCARDIUM), seen mostly in children and young adults in the TROPICAL CLIMATE. The fibrous tissue extends from the apex toward and often involves the HEART VALVES causing restrictive blood flow into the respective ventricles (CARDIOMYOPATHY, RESTRICTIVE).
| Excerpt | Relevance | Reference |
|---|---|---|
| "We sought to evaluate the effects of spironolactone on neurohumoral factors and left ventricular remodeling in patients with congestive heart failure (CHF)." | 9.09 | Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. ( Fujii, M; Hayashi, M; Kinoshita, M; Mabuchi, N; Maeda, K; Matsui, T; Matsumoto, T; Ohnishi, M; Sawaki, M; Tsutamoto, T; Tsutsui, T; Wada, A, 2001) |
| "These results show that in old normotensive rats, spironolactone can markedly prevent cardiac and, to a lesser extent, arterial fibrosis and improve arterial stiffness, despite a lack of hypotensive effect." | 7.71 | Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats. ( Benetos, A; Labat, C; Lacolley, P; Ledudal, K; Lucet, B; Safar, ME, 2001) |
| "Aldosterone has a variety of detrimental effects on the heart and vasculature and is increasingly recognized as an important target in chronic heart failure, as illustrated by the Randomized Aldactone Evaluation Study." | 6.42 | The role of aldosterone in heart failure and the clinical benefits of aldosterone blockade. ( Davies, JI; Dawson, A; Struthers, AD, 2004) |
| "Aldosterone was shown to promote cardiac fibrosis in various experimental models." | 6.41 | Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship. ( Alla, F; Dousset, B; Zannad, F, 2001) |
| "Mortality of patients with severe congestive heart failure (CHF) is still high despite combined treatment with angiotensin-converting enzyme (ACE) inhibitors, diuretics, and digitalis." | 6.40 | [Spironolactone: renaissance of anti-aldosterone therapy in heart failure?]. ( Brilla, CG; Rupp, H; Scheer, C; Schencking, M, 1997) |
| "Aldosterone has been shown to have an acute arrhythmogenic effect as well as a potential detrimental effect on baroreflex function, a marker of prognosis in CHF." | 6.39 | Aldosterone escape during ACE inhibitor therapy in chronic heart failure. ( Struthers, AD, 1995) |
| "Thus, in rats with aldosteronism, in which a reduction in effective refractory period was not evident, the mechanism for VA susceptibility is presumably linked to a decrease in conduction velocity and/or increased dispersion of refractoriness, probably caused by consequential myocardial fibrosis." | 5.37 | Spironolactone prevents the inducibility of ventricular tachyarrhythmia in rats with aldosteronism. ( Bellary, SR; de Jongh Curry, AL; Deshmukh, PA; Kamalov, G; Magotra, M; Schwender, FT; Sun, Y; Weber, KT, 2011) |
| "Losartan treatment decreased systolic pressure and yellow-red collagen fiber content in all areas, whereas spironolactone treatment decreased green collagen fiber content without decreasing systolic pressure." | 5.29 | Left ventricular fibrosis in renovascular hypertensive rats. Effect of losartan and spironolactone. ( Appay, MD; Bariety, J; Heudes, D; Hinglais, N; Michel, JB; Nicoletti, A; Philippe, M; Sassy-Prigent, C, 1995) |
| "We sought to evaluate the effects of spironolactone on neurohumoral factors and left ventricular remodeling in patients with congestive heart failure (CHF)." | 5.09 | Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. ( Fujii, M; Hayashi, M; Kinoshita, M; Mabuchi, N; Maeda, K; Matsui, T; Matsumoto, T; Ohnishi, M; Sawaki, M; Tsutamoto, T; Tsutsui, T; Wada, A, 2001) |
| "These results show that in old normotensive rats, spironolactone can markedly prevent cardiac and, to a lesser extent, arterial fibrosis and improve arterial stiffness, despite a lack of hypotensive effect." | 3.71 | Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats. ( Benetos, A; Labat, C; Lacolley, P; Ledudal, K; Lucet, B; Safar, ME, 2001) |
| "The role of renin-angiotensin-aldosterone system in cardiac remodelling was studied in isoproterenol-induced cardiac hypertrophy in rats." | 3.71 | Spironolactone and captopril attenuates isoproterenol-induced cardiac remodelling in rats. ( Casis, O; Echevarria, E; Espiña, L; Gallego, M; Iriarte, MM; Vegas, L, 2001) |
| "Aldosterone has a variety of detrimental effects on the heart and vasculature and is increasingly recognized as an important target in chronic heart failure, as illustrated by the Randomized Aldactone Evaluation Study." | 2.42 | The role of aldosterone in heart failure and the clinical benefits of aldosterone blockade. ( Davies, JI; Dawson, A; Struthers, AD, 2004) |
| "Aldosterone was shown to promote cardiac fibrosis in various experimental models." | 2.41 | Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship. ( Alla, F; Dousset, B; Zannad, F, 2001) |
| "Mortality of patients with severe congestive heart failure (CHF) is still high despite combined treatment with angiotensin-converting enzyme (ACE) inhibitors, diuretics, and digitalis." | 2.40 | [Spironolactone: renaissance of anti-aldosterone therapy in heart failure?]. ( Brilla, CG; Rupp, H; Scheer, C; Schencking, M, 1997) |
| "Aldosterone has been shown to have an acute arrhythmogenic effect as well as a potential detrimental effect on baroreflex function, a marker of prognosis in CHF." | 2.39 | Aldosterone escape during ACE inhibitor therapy in chronic heart failure. ( Struthers, AD, 1995) |
| "Hypertension results in left ventricular hypertrophy and cardiac dysfunction." | 1.51 | Myocardial global longitudinal strain: An early indicator of cardiac interstitial fibrosis modified by spironolactone, in a unique hypertensive rat model. ( Coffey, S; Leader, CJ; Moharram, M; Sammut, IA; Walker, RJ; Wilkins, GW, 2019) |
| "Thus, in rats with aldosteronism, in which a reduction in effective refractory period was not evident, the mechanism for VA susceptibility is presumably linked to a decrease in conduction velocity and/or increased dispersion of refractoriness, probably caused by consequential myocardial fibrosis." | 1.37 | Spironolactone prevents the inducibility of ventricular tachyarrhythmia in rats with aldosteronism. ( Bellary, SR; de Jongh Curry, AL; Deshmukh, PA; Kamalov, G; Magotra, M; Schwender, FT; Sun, Y; Weber, KT, 2011) |
| "Spironolactone has been noted to attenuate cardiac fibrosis." | 1.35 | Spironolactone attenuates experimental uremic cardiomyopathy by antagonizing marinobufagenin. ( Bagrov, AY; Cooper, CJ; El-Okdi, N; Elkareh, J; Fedorova, OV; Gohara, S; Gupta, S; Haller, S; Malhotra, D; Periyasamy, SM; Shapiro, JI; Shidyak, A; Taleb, M; Tian, J; Xie, Z, 2009) |
| "Thus aldosterone and salt treatment in uninephrectomized rats led to severe hypertension and the development of a vascular inflammatory phenotype in the heart, which may represent one mechanism by which aldosterone contributes to myocardial disease." | 1.31 | Aldosterone induces a vascular inflammatory phenotype in the rat heart. ( Blomme, EA; Delyani, JA; Frierdich, GE; Kekec, BK; McMahon, EG; Nachowiak, DA; Rocha, R; Rudolph, AE, 2002) |
| "DOCA-salt hypertension was induced in 8-wk-old male Wistar rats by uninephrectomy and administration of DOCA (25 mg every fourth day, subcutaneously) and 1% NaCl in the drinking water for 4 wk." | 1.30 | Reversal of cardiac fibrosis in deoxycorticosterone acetate-salt hypertensive rats by inhibition of the renin-angiotensin system. ( Brown, L; Duce, B; Miric, G; Sernia, C, 1999) |
| "Losartan treatment decreased systolic pressure and yellow-red collagen fiber content in all areas, whereas spironolactone treatment decreased green collagen fiber content without decreasing systolic pressure." | 1.29 | Left ventricular fibrosis in renovascular hypertensive rats. Effect of losartan and spironolactone. ( Appay, MD; Bariety, J; Heudes, D; Hinglais, N; Michel, JB; Nicoletti, A; Philippe, M; Sassy-Prigent, C, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (20.00) | 18.2507 |
| 2000's | 12 (60.00) | 29.6817 |
| 2010's | 4 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Leader, CJ | 1 |
| Moharram, M | 1 |
| Coffey, S | 1 |
| Sammut, IA | 1 |
| Wilkins, GW | 1 |
| Walker, RJ | 1 |
| Cai, J | 1 |
| Chen, X | 2 |
| Chen, L | 1 |
| Zheng, G | 1 |
| Zhou, H | 1 |
| Zhou, X | 1 |
| Mori, T | 1 |
| Kurumazuka, D | 1 |
| Matsumoto, C | 1 |
| Shirakawa, H | 1 |
| Kimura, S | 1 |
| Kitada, K | 1 |
| Kobayashi, K | 1 |
| Matsuda, H | 1 |
| Hayashi, T | 1 |
| Kitaura, Y | 1 |
| Matsumura, Y | 1 |
| Tian, J | 1 |
| Shidyak, A | 1 |
| Periyasamy, SM | 1 |
| Haller, S | 1 |
| Taleb, M | 1 |
| El-Okdi, N | 1 |
| Elkareh, J | 1 |
| Gupta, S | 1 |
| Gohara, S | 1 |
| Fedorova, OV | 1 |
| Cooper, CJ | 1 |
| Xie, Z | 1 |
| Malhotra, D | 1 |
| Bagrov, AY | 1 |
| Shapiro, JI | 1 |
| Habibi, J | 1 |
| DeMarco, VG | 1 |
| Ma, L | 1 |
| Pulakat, L | 1 |
| Rainey, WE | 1 |
| Whaley-Connell, AT | 1 |
| Sowers, JR | 1 |
| Deshmukh, PA | 1 |
| Bellary, SR | 1 |
| Schwender, FT | 1 |
| Kamalov, G | 1 |
| Magotra, M | 1 |
| de Jongh Curry, AL | 1 |
| Sun, Y | 1 |
| Weber, KT | 1 |
| Sanderson, JE | 1 |
| Rocha, R | 1 |
| Rudolph, AE | 1 |
| Frierdich, GE | 1 |
| Nachowiak, DA | 1 |
| Kekec, BK | 1 |
| Blomme, EA | 1 |
| McMahon, EG | 1 |
| Delyani, JA | 1 |
| Martin, N | 1 |
| Ott, R | 1 |
| Klues, HG | 1 |
| Dawson, A | 1 |
| Davies, JI | 1 |
| Struthers, AD | 2 |
| Nicoletti, A | 1 |
| Heudes, D | 1 |
| Hinglais, N | 1 |
| Appay, MD | 1 |
| Philippe, M | 1 |
| Sassy-Prigent, C | 1 |
| Bariety, J | 1 |
| Michel, JB | 1 |
| Brilla, CG | 1 |
| Schencking, M | 1 |
| Scheer, C | 1 |
| Rupp, H | 1 |
| Brown, L | 1 |
| Duce, B | 1 |
| Miric, G | 1 |
| Sernia, C | 1 |
| Zannad, F | 2 |
| Lacolley, P | 1 |
| Safar, ME | 1 |
| Lucet, B | 1 |
| Ledudal, K | 1 |
| Labat, C | 1 |
| Benetos, A | 1 |
| Tsutamoto, T | 1 |
| Wada, A | 1 |
| Maeda, K | 1 |
| Mabuchi, N | 1 |
| Hayashi, M | 1 |
| Tsutsui, T | 1 |
| Ohnishi, M | 1 |
| Sawaki, M | 1 |
| Fujii, M | 1 |
| Matsumoto, T | 1 |
| Matsui, T | 1 |
| Kinoshita, M | 1 |
| Gallego, M | 1 |
| Espiña, L | 1 |
| Vegas, L | 1 |
| Echevarria, E | 1 |
| Iriarte, MM | 1 |
| Casis, O | 1 |
| Dousset, B | 1 |
| Alla, F | 1 |
| Satoh, M | 1 |
| Nakamura, M | 1 |
| Saitoh, H | 1 |
| Satoh, H | 1 |
| Akatsu, T | 1 |
| Iwasaka, J | 1 |
| Masuda, T | 1 |
| Hiramori, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| E_Stethoscope : Portable Digital Auscultation Based on Wireless Sensor Node to Diagnose Diastolic Dysfunction in Hypertensive Heart Disease[NCT02809040] | 60 participants (Anticipated) | Observational | 2015-02-28 | Active, not recruiting | |||
| A Prospective Randomized Placebo-controlled Study of the Effect of Eplerenone on Left Ventricular Diastolic Function in Women Receiving Anthracycline Therapy for Breast Cancer[NCT01708798] | Phase 2/Phase 3 | 44 participants (Actual) | Interventional | 2014-05-31 | Terminated (stopped due to Futility) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for spironolactone and Endomyocardial Fibrosis
| Article | Year |
|---|---|
The role of aldosterone in heart failure and the clinical benefits of aldosterone blockade.
Topics: Aldosterone; Autonomic Nervous System Diseases; Endomyocardial Fibrosis; Eplerenone; Heart Failure; | 2004 |
Aldosterone escape during ACE inhibitor therapy in chronic heart failure.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Arrhythmias, Cardiac; Chronic Disease; Drug T | 1995 |
[Spironolactone: renaissance of anti-aldosterone therapy in heart failure?].
Topics: Animals; Diuretics; Endomyocardial Fibrosis; Heart Failure; Humans; Microcirculation; Mineralocortic | 1997 |
Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; An | 2001 |
Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; An | 2001 |
Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; An | 2001 |
Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; An | 2001 |
1 trial available for spironolactone and Endomyocardial Fibrosis
| Article | Year |
|---|---|
Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure.
Topics: Aged; Aldosterone; Cardiac Volume; Endomyocardial Fibrosis; Female; Follow-Up Studies; Heart Failure | 2001 |
15 other studies available for spironolactone and Endomyocardial Fibrosis
| Article | Year |
|---|---|
Myocardial global longitudinal strain: An early indicator of cardiac interstitial fibrosis modified by spironolactone, in a unique hypertensive rat model.
Topics: Animals; Cardiotonic Agents; Disease Models, Animal; Echocardiography; Endomyocardial Fibrosis; Hype | 2019 |
Anti-Fibrosis Effect of Relaxin and Spironolactone Combined on Isoprenaline-Induced Myocardial Fibrosis in Rats via Inhibition of Endothelial-Mesenchymal Transition.
Topics: Actins; Animals; Antigens, CD; Cadherins; Cardiotonic Agents; Collagen Type I; Collagen Type III; Dr | 2017 |
Dietary salt restriction activates mineralocorticoid receptor signaling in volume-overloaded heart failure.
Topics: Aldosterone; Animals; Atrial Natriuretic Factor; Body Weight; Cell Size; Contraindications; Diet, So | 2009 |
Spironolactone attenuates experimental uremic cardiomyopathy by antagonizing marinobufagenin.
Topics: Animals; Bufanolides; Canrenone; Cardiomyopathies; Cardiotonic Agents; Cells, Cultured; Disease Mode | 2009 |
Mineralocorticoid receptor blockade improves diastolic function independent of blood pressure reduction in a transgenic model of RAAS overexpression.
Topics: Animals; Blood Pressure; Cardiomegaly; Endomyocardial Fibrosis; Male; Mineralocorticoid Receptor Ant | 2011 |
Spironolactone prevents the inducibility of ventricular tachyarrhythmia in rats with aldosteronism.
Topics: Aldosterone; Animals; Blood Pressure; Body Weight; Collagen; Electric Stimulation; Electrocardiograp | 2011 |
New treatments for myocardial fibrosis.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Canrenone; Clinical Trials as Topic; | 2002 |
Aldosterone induces a vascular inflammatory phenotype in the rat heart.
Topics: Aldosterone; Animals; Blood Pressure; Chemokine CCL2; Coronary Vessels; Cyclooxygenase 2; Endomyocar | 2002 |
[Idiopathic hypereosinophilia with cardiac involvement].
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cardiomyopathy, Restrictiv | 2004 |
Left ventricular fibrosis in renovascular hypertensive rats. Effect of losartan and spironolactone.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biochemical Phen | 1995 |
Reversal of cardiac fibrosis in deoxycorticosterone acetate-salt hypertensive rats by inhibition of the renin-angiotensin system.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; | 1999 |
[Anti-aldosterone: the evidence of the RALES study].
Topics: Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Cardiac Output, Low; Diuretics; Endomyocardial | 2000 |
Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats.
Topics: Age Factors; Aldosterone; Animals; Aorta; Carotid Arteries; Endomyocardial Fibrosis; Fibrosis; Hemod | 2001 |
Spironolactone and captopril attenuates isoproterenol-induced cardiac remodelling in rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Captopril; Cardiomegaly; Collagen | 2001 |
Aldosterone synthase (CYP11B2) expression and myocardial fibrosis in the failing human heart.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Collagen; Cytochrome P-450 CYP11B2; Diuretics; Drug | 2002 |